# OBI Pharma

Source: https://onco.cc/companies/obi-pharma/  
OnCo record `obi-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OBI Pharma is a Taiwanese biotech that turns the tumour sugar Globo H into cancer vaccines and antibody-drug conjugates, best known for the breast cancer vaccine adagloxad simolenin.

## Summary

OBI Pharma, listed on the Taipei Exchange, develops therapies against Globo-series glycolipids that are over-expressed on many epithelial tumours. Adagloxad simolenin (OBI-822), a Globo H vaccine, is in a phase 3 trial in Globo H-high triple-negative breast cancer. Its pipeline also includes OBI-992, a TROP2 antibody-drug conjugate, and OBI-902, a Globo H-directed conjugate, together with the ThioBridge linker platform.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: OBI Pharma, Inc.; 台灣浩鼎; TPEx:4174
- Tags: drug-maker
- HQ: Taipei
- Type: biotech
- Website: https://www.obipharma.com/

## Sources

- Official website: https://www.obipharma.com/

## Connected records

- drugs: [Adagloxad simolenin](https://onco.cc/drugs/adagloxad-simolenin/), [OBI-902](https://onco.cc/drugs/obi-902/), [OBI-992](https://onco.cc/drugs/obi-992/)

---
JSON: https://onco.cc/api/v1/entities/obi-pharma.json